PharmaEngine, Inc. (TPEX:4162)
Taiwan · Delayed Price · Currency is TWD 53.60
+0.60 (1.13%)
May 29, 2026, 1:30 PM CST
PharmaEngine Cash Flow Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | 422.55 | 387.64 | 1,751 | 274.65 | 318.78 | 426.03 |
Depreciation & Amortization | 10.44 | 10.05 | 9.31 | 9.02 | 8.61 | 10.26 |
Loss (Gain) From Sale of Investments | - | - | - | -5.53 | -45.46 | -0.83 |
Stock-Based Compensation | 0.23 | 0.4 | 1.3 | 3.38 | 2.37 | 0.09 |
Provision & Write-off of Bad Debts | 0.01 | 0.02 | 0 | -0 | 0.01 | -0.22 |
Other Operating Activities | -267.15 | -276.88 | 344.77 | -33.31 | -54.79 | -81.69 |
Change in Accounts Receivable | -3.1 | 1,582 | -1,670 | -13.83 | 0.13 | 541.22 |
Change in Inventory | -8.39 | -11.5 | -12.48 | 18.47 | -28.94 | 19.31 |
Change in Accounts Payable | - | 35.58 | - | - | -2.05 | 8.62 |
Change in Other Net Operating Assets | 23.89 | -0.27 | 32.89 | 4.12 | 3.36 | 6.87 |
Operating Cash Flow | 178.47 | 1,727 | 456.73 | 256.97 | 202.01 | 929.67 |
Operating Cash Flow Growth | -91.82% | 278.09% | 77.74% | 27.21% | -78.27% | 1335.36% |
Capital Expenditures | -0.28 | -0.28 | -0.81 | -0.41 | -3.44 | -0.23 |
Sale (Purchase) of Intangibles | - | - | -0.6 | - | -0.5 | - |
Investment in Securities | -991.81 | -266.18 | -114.67 | -854.48 | -183.98 | -105 |
Other Investing Activities | -0.05 | -0.19 | 0.55 | -0.59 | -0.2 | -1.77 |
Investing Cash Flow | -992.14 | -266.66 | -115.54 | -855.48 | -188.12 | -107 |
Long-Term Debt Repaid | - | -8.45 | -7.67 | -7.54 | -8 | -9.6 |
Net Debt Issued (Repaid) | -8.67 | -8.45 | -7.67 | -7.54 | -8 | -9.6 |
Repurchase of Common Stock | - | - | - | - | - | -133.41 |
Common Dividends Paid | -861.92 | -861.92 | -215.44 | -287.19 | -387.71 | -363.99 |
Financing Cash Flow | -870.6 | -870.37 | -223.11 | -294.73 | -395.71 | -507 |
Foreign Exchange Rate Adjustments | - | - | - | - | - | -0.75 |
Net Cash Flow | -1,684 | 589.83 | 118.08 | -893.24 | -381.81 | 314.93 |
Free Cash Flow | 178.19 | 1,727 | 455.92 | 256.56 | 198.57 | 929.44 |
Free Cash Flow Growth | -91.83% | 278.70% | 77.71% | 29.20% | -78.64% | 1335.01% |
Free Cash Flow Margin | 18.49% | 189.44% | 18.07% | 33.42% | 30.34% | 141.94% |
Free Cash Flow Per Share | 1.24 | 11.99 | 3.17 | 1.78 | 1.38 | 6.42 |
Cash Interest Paid | 0.14 | 0.14 | 0.18 | 0.31 | 0.08 | 0.21 |
Cash Income Tax Paid | 396.28 | 396.28 | 61.37 | 92.35 | 124.42 | 200.65 |
Levered Free Cash Flow | 56 | 1,617 | -19.65 | 159.87 | 105.29 | 723.9 |
Unlevered Free Cash Flow | 56.2 | 1,617 | -19.54 | 160.06 | 105.34 | 724.04 |
Change in Working Capital | 12.39 | 1,606 | -1,650 | 8.76 | -27.51 | 576.02 |